Talia Puzantian, PharmD, BCPP

Clinical Guidance

Opioid Withdrawal Management

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Getting patients with opioid use disorder (OUD) completely off opioids, so-called “detox,” is generally not advisable.

Clinical Guidance

How to Ask DSM-5 Focused Questions for Opioid Use Disorder

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Like all substance use disorders, opioid use disorder (OUD), defined by the DSM-5, includes 11 criteria.

Clinical Guidance

Opioid Use Disorder: How to Conduct the Initial Assessment

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

As with any psychiatric interview, start by building an alliance and showing interest in your patient in a general way.

Clinical Guidance

Opioid Use Disorder: Initial Evaluation Template

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

This template can be downloaded and adapted for your charting, or you can use it as a guide to remind you of important topics to cover during the initial interview.

Clinical Guidance

Overview of Treatment Options for Opioid Use Disorder

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

As treatment options for patients with opioid use disorder (OUD) expand, it’s important to have a handy overview available to guide your conversations with patients.

Clinical Guidance

Xylazine: The Basics

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The illicit opioid supply has become increasingly unpredictable.

Clinical Guidance

Opioids: The Basics of Street Drugs

January 1, 2025

Daniel Carlat, MD, Noah Capurso, MD, MHS, and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The global supply of illicit opioids is rapidly shifting and unstable.

Fact Sheet

Medication Tapering Instructions

January 1, 2025

Daniel Carlat, MD, Michael Weaver, MD, FASAM, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Regardless of which withdrawal regimen you choose, if your patient doesn’t understand the schedule of administration, they are unlikely to be successful.

Fact Sheet

Medical Issues and Alcohol Use Disorder

January 1, 2025

Daniel Carlat, MD, Michael Weaver, MD, FASAM, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

While you will not be treating most medical complications of alcohol use, it’s important to ask patients about these things, especially as part of the motivational interviewing strategy.

Fact Sheet

How to Use Phenobarbital to Manage Alcohol Withdrawal

January 1, 2025

Daniel Carlat, MD, Michael Weaver, MD, FASAM, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Phenobarbital is becoming more popular as a strategy for managing alcohol withdrawal syndrome (AWS) as clinicians gain more experience with it.